In patients with uncontrolled asthma, a LAMA combined with an ICS and LABA in a single inhaler improved FEV1 and reduced exacerbations, according to data presented at ERS 2019 and reported by Healio.com.
- Patients in the TRIMARAN trial received beclomethasone dipropionate 100 µg/formoterol fumarate 6 µg twice daily for two weeks.
- Patients in the TRIGGER trial received beclomethasone dipropionate 200 µg/formoterol fumarate 6 µg in TRIGGER twice daily for two weeks.
- Patients in TRIMARAN were then continued on standard combined therapy at the same dose (n = 576) or switched to extrafine beclomethasone dipropionate 100 µg/formoterol fumarate 6 µg/glycopyrronium 10 µg twice daily (n = 579) via a pressurized metered-dose inhaler.
- Patients in TRIGGER continued on the same dose of standard combined therapy (n = 576) or switched to extrafine beclomethasone dipropionate 200 µg/formoterol fumarate 6 µg/glycopyrronium 10 µg twice daily via a pressurized metered-dose inhaler (n = 576) or switched to open-label standard combined therapy in a pressurized metered-dose inhaler plus tiotropium 2.5 µg twice daily via a soft mist inhaler (n = 288).
- The researchers found that predose FEV1 at 26 weeks improved in the triple therapy group by 57 mL in TRIMARAN and by 73 mL in TRIGGER vs. standard combined therapy.